Amgen Inc. (AMGN) Presents at Morgan Stanley 23rd Annual Global Healthcare Conference

Terence Flynn
Equity Analyst

Great. Good morning, everybody. I’m Terence Flynn, Morgan Stanley’s large-cap U.S. biopharma analyst. Very pleased to be hosting Amgen this morning. Joining us from the company, we have Peter Griffith, the company’s CFO; and Kave Niksefat, who is the company’s SVP of Global Marketing. Thank you both so much for being here today.

For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales rep.

With that, I’m going to turn over to Peter for some opening remarks, and then we’ll get into it.

Peter Griffith
Executive VP & CFO

Thank you, Terence. We’re delighted to be here with you and the Morgan Stanley team today. We’re grateful for the relationship with Morgan Stanley.

We’re investing in innovation and science that enable longer, healthier lives. We’re executing across our business with breadth and depth in four therapeutic areas, along with our leading biosimilars portfolio. We’re delivering strong results. Second quarter revenues grew 9% and volume was up 13%. Non-GAAP EPS, up 21% year-over-year. Fifteen products achieved double-digit or better growth in the second quarter, and 14 products are annualizing at $1 billion or more based on the second quarter product sales.

So let me start with an overview of the business, highlighting some of the key drivers across both the end market portfolio and across the pipeline in each one of the therapeutic areas. So beginning with general medicine, Repatha and EVENITY both delivered over 30% growth in